PharVision Advisers’s Sarepta Therapeutics SRPT Stock Holding History

PharVision Advisers’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-18,523	Closed	-$357K	–	988
2025 Q3	$357K	Buy	+18,523	New	+$330K	0.2%	134

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

PharVision Advisers's SRPT Position: Q4 2025 in Review

PharVision Advisers sold out of Sarepta Therapeutics (SRPT) in Q4 2025, closing a stake of 18,523 shares — an estimated $357K sold.

PharVision Advisers first reported a position in SRPT in Q3 2025 and held it in 1 quarter. The position peaked at $357K in Q3 2025. 346 funds tracked by Wall St. Rank hold SRPT as of Q4 2025.

PharVision Advisers reported no remaining Sarepta Therapeutics position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 18,523 Sarepta Therapeutics shares in Q4 2025, an estimated $357K.
PharVision Advisers first reported a position in Sarepta Therapeutics in Q3 2025 and held it in 1 quarter.
PharVision Advisers's Sarepta Therapeutics position peaked at $357K in Q3 2025.
346 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.